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Abstract
Background: Transarterial embolization (TAE) is a therapeutic option for patients with a high risk of recurrent
bleeding after endoscopic haemostasis. The aim of our prospective study was a preliminary assessment of the
safety, efficacy, and clinical outcomes following preventive TAE in patients with non-variceal acute upper
gastrointestinal bleeding (NVUGIB) with a high risk of recurrent bleeding after endoscopic haemostasis.
Methods: Preventive visceral angiography and TAE were performed after endoscopic haemostasis on patients with
NVUGIB who were at a high risk of recurrent bleeding (PE+ group). The comparison group consisted of similar
patients who only underwent endoscopic haemostasis, without preventive TAE (PE− group). The technical success of
preventive TAE, the completeness of haemostasis, the incidence of rebleeding and the need for surgical intervention
and the main outcomes were compared between the groups.
Results: The PE+ group consisted of 25 patients, and the PE− group of 50 patients, similar in age (median age 66 vs.
63 years), gender and comorbid conditions. The ulcer size at endoscopy was not significantly different (median of
152 mm vs. 127 mm). The most frequent were Forest II type ulcers, 44% in both groups. The distribution of the Forest
grade was even. The median haemoglobin on admission was 8, 2 g/dl vs. 8,7 g/dl, p = 0,482, erythrocyte count was
2,7 × 1012/L vs. 2,9 × 1012/L, p = 0,727. The shock index and Rockall scores were similar, as well as and transfusion – on
average, four units of packed red blood cells for the majority of patients in both groups, however, significantly more
fresh frozen plasma was transfused in the PE− group, p = 0,013. The rebleeding rate was similar, while surgical
treatment was needed notably more often in the PE- group, 8% vs. 35% accordingly, p = 0,012. The median
ICU stay was 3 days, hospital stay – 6 days vs. 9 days, p = 0.079. The overall mortality reached 20%; in the PE+ group it
was 4%, not reaching a statistically significant difference.
Conclusion: Preventive TAE is a feasible, safe and effective minimally invasive type of haemostasis decreasing the risk
of repeated bleeding and preparing the patient for the definitive surgical intervention when indicated.
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Background
Rebleeding is one of the most serious complications of
endoscopic haemostasis in patients with NVUGIB. The
prevention of rebleeding is, therefore, crucial in the
treatment of NVUGIB due to a considerable increase in
mortality in case of failure.
Over the past two decades, TAE has become the first-
line therapy for the management of upper gastrointestinal
bleeding that is refractory to endoscopic haemostasis [1].
Despite conservative medical treatment or endoscopic
intervention severe rebleeding occurs in 5−10% of
patients, requiring surgery or TAE [2], and TAE has been
increasingly used as an alternative to surgery in the upper
NVUGIB refractory to endoscopic therapy. The method
has been associated with a lower mortality and complica-
tion rate compared to surgery [3, 4]. Although early
aggressive endoscopic haemostasis is generally the first
choice of treatment in the cohort of patients who are at a
high risk of rebleeding, additional methods of haemostasis
may be needed to achieve a favourable outcome. Due to
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former evidence that in the situation of acute bleeding, it
is not always possible to perform TAE successfully as an
additional method of haemostasis, the preventive mode of
TAE was proposed as one of the possible ways to achieve
complete haemostasis, decrease the rebleeding rate, the
need for surgical intervention, complications and
mortality. A possible benefit of using TAE as a pre-
ventive measure in patients who are considered to
have a high risk of rebleeding after endoscopic
haemostasis has never been properly examined. One
of the main arguments in favour of preventive TAE is
speculation that rebleeding after a temporarily suc-
cessful endoscopic therapy might be caused by an in-
adequate endoscopic treatment resulting in a residual
arterial flow beneath the ulcer. In this subgroup of
patients, preventive TAE performed shortly after
endoscopic haemostasis is achieved, could result in a
decreased rate of rebleeding and reduced mortality
thereby [5]. The aim of our prospective study was a
preliminary assessment of the safety, efficacy, and
clinical outcomes following preventive TAE in NVU-
GIB patients with a high risk of recurrent bleeding
after endoscopic haemostasis.
Methods
The preparation of the study included an analysis of the
medical charts of 379 patients who were emergently
admitted to the Riga East University Hospital with
NVUGIB in the period from 2010 to 2013, (Fig. 1). The
results suggested that the patients with NVUGIB who
were at a high risk of rebleeding after emergent endo-
scopic haemostasis had Forrest I-IIb type of ulcer and
the Rockall score ≥ 5. These two criteria were important
for further grouping and inclusion of patients in the
prospective study. Informed consent was obtained from
the patients who underwent endovascular treatment.
Preventive visceral angiography and TAE were per-
formed on patients with acute NVUGIB who were
considered to be at a high risk of recurrent bleeding
after endoscopic haemostasis according to the evidence
of Forest I-IIb ulcer and Rockall score ≥ 5 (PE+ group).
The comparison group consisted of similar patients who
underwent only endoscopic haemostasis, patients who
did not agree to undergo preventive TAE with a similar
prognosis of high rebleeding risk after endoscopic
hemostasis and similar comorbid conditions (PE− group).
The exclusion criterion was terminal end stage renal
Fig. 1 Patient recruitment chart
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disease. The participants were enrolled and assigned to
their treatment by the consensus among the consultant
surgeon, consultant radiologist and duty endoscopy
specialist. Endoscopic combination therapy (injection
of diluted adrenaline 1:10,000, treatment with a heater
probe, and/or hemoclip) followed by a 72-h infusion
of esomeprazole (80 mg bolus followed by 8 mg/h)
was applied to all patients. Blood transfusion was
given if haemoglobin was lower than 9.7 g/dl. Patients
were closely monitored at ICU.
Technical approach
The technical goal was preventive embolization of the
left gastric artery or the gastroduodenal artery (de-
pending on the ulcer localization) within 24 h of
endoscopic haemostasis, achieving a decrease of the
arterial flow in the tissue beneath the ulcer. Usually,
proximal embolization of the left gastric artery with
coil and/or sandwich type TAE embolization of the
gastroduodenal artery was used. In cases with the
ulcer localized in the smaller or greater curvature or
the gastric fundus – the left gastric artery was obliter-
ated; in gastric antral, pyloric or duodenal ulcers –
the gastroduodenal artery was embolized. Rebleeding
was defined as a presence of hematemesis, blood
from the nasogastric tube, or melena associated with
a fall in haemoglobin of more than 0.8 g/dl (not ex-
plained by hemodilution) or arterial hypotension after
primary endoscopy. If the therapeutic endoscopy were
insufficient to comparison haemorrhage (technically
difficult primary therapeutic endoscopy or signs of ex-
sanguination), TAE or surgical haemostasis could be
performed without being preceded by repeated endos-
copy. The complication rate, recurrence of bleeding,
and the need for repeat endoscopic therapy or surgery
were the variables for the statistical analysis in
groups. In-hospital mortality rate among the groups
was analysed, and the patients who were excluded
from the study. The study was approved by the local
research ethics committee and followed the declar-
ation of Helsinki [Helsinki declaration]. All authors
had access to the study data and have reviewed and
approved the final manuscript.
Results
During the 32-month period of inclusion 75 patients re-
ceived endoscopic haemostasis for acute high-risk NVU-
GIB and were evaluated according to the inclusion
criteria. The PE+ group consisted of 25 patients, and the
PE− group of 50 patients. The median age of patients
was 66 years (IQR 74–57) vs. 63 (IQR 75–52) years
without a statistically significant difference. There was
no difference in gender and comorbid conditions, in-
cluding the presence of cancer, liver and pulmonary
diseases, which were rare in both groups, Table 1.
Endoscopic findings were not different, with the median
ulcer size of 152 mm (IQR 400–79) vs. 127 mm (IQR
225–79). The bleeding site was similar in both groups.
Gastric ulcer was the cause of bleeding in 52% of
patients from the PE + group, and 54% of patients from
the PE− group, p = 0,870. Duodenal ulcer was the cause
of bleeding in 48 and 46% of patients respectively. The
most commonly found ulcers were Forest II type in 44%
of cases in both groups. The distribution of the Forest
grade was even, Table 1. The median haemoglobin level
on admission was 8,2 g/dl (IQR 11–7) vs. 8,7 g/dl (IQR
10–5,8), p = 0,482 and the erythrocyte count was 2,7 ×
1012/L (IQR 3,5–2,1) vs. 2,9 × 1012/L (IQR 3,7–2,1),
p = 0,727 including similar shock index and Rockall
scores for both groups. The Rockall score values and
shock index values were evenly distributed in the
groups, Table 2. The use of anticlotting drugs in the
groups was also similar, Table 3. Transfusion support was
needed for the majority of patients, using, on average, four
units of packed red blood cells (PRBC) in both groups and
significantly more fresh frozen plasma (FFP) in the PE−
group, p = 0,013. The rebleeding rate was similar, however,
surgical treatment in patients who did not undergo
embolization was needed significantly more often, 8% vs.
35,4%, p = 0,012. The median ICU stay was 3 days, and






Age, years, median (IQR) 66 (74-57) 63 (75-52) 0,393
Gender/Male, no. of patients 16 (64%) 34 (68%) 0,797
Comorbidities, no. of patients 18 (72%) 35 (70%) 0,858
Heart disease, no. of patients 13 (52%) 30 (60%) 0,509
Kidney disease, no. of patients 3 (12%) 6 (12%) 1,000
Liver disease, no. of patients 2 (8%) 4 (8%) 1,000
Cancer, no. of patients 1 (4%) 1 (2%) 1,000
Metabolic disease, no. of patients 4 (16%) 10 (20%) 0,763
Respiratory disease, no. of patients 2 (8%) 4 (8%) 1,000
Cerebral disease, no. of patients 6 (24%) 11 (22%) 0,881
Ulcer size, mm, median (IQR) 152 (400-79) 127 (225-79) 0,737
Forrest IA, no. of patients 5 (20%) 11 (22%) 0,937
Forrest IB, no. of patients 4 (16%) 7 (14%) 0,937
Forrest IIA, no. of patients 11 (44%) 22 (44%) 0,937
Forrest IIB, no. of patients 5 (20%) 10 (20%) 0,937
HGB, g/dl, median (IQR) 8,2 (11-7) 8,7 (10-5,8) 0,482
ERY, ×1012/L, median (IQR) 2,7 (3,5-2,1) 2,9 (3,7-2,1) 0,727
INR, ratio, median (IQR) 1,07 (1,25-1) 1,16 (1,34-1) 0,318
Shock index, median (IQR) 0,93 (1,2-0,67) 0,86 0,567
Rockall score, points, median (IQR) 6 (5-7) 6 0,608
Kaminskis et al. World Journal of Emergency Surgery  (2017) 12:3 Page 3 of 5
the hospital stay did not differ either, 6 (IQR 10–6) vs. 9
(IQR 11–6), p = 0,079. Mortality for all patients reached
20%, however, in the PE+ group it was 4%, though not
reaching a statistically significant difference. The main
outcomes are displayed in Table 4.
Discussion
Management of the upper gastrointestinal bleeding is
still a challenge despite the recognized leading role of
endoscopic hemostasis [6]. All improvements in the
medical and endoscopic treatment are not sufficiently ef-
fective in treating the aging population with comorbid
conditions that often has concomitant treatment with
nonsteroidal anti-inflammatory or anti-clotting drugs
[1]. The risk of rebleeding increases when Forest I-II
ulcers diagnosed during endoscopic hemostasis is associ-
ated with different comorbid conditions and medication
that interferes with the clotting system [7–9]. When
rebleeding happens, several options are recommended –
emergent repeated endoscopy, emergent TAE or surgical
intervention [7, 10]. Preventive TAE is an additional op-
tion to decrease the rebleeding rate after an endoscopic
hemostasis attempt. Nevertheless, the exact criteria for
the selection of indications and strong evidence support-
ing the rational to use this method of hemostasis are
insufficient [11]. Advances in catheter-based techniques
and newer embolic agents, as well as the recognition of
the efficiency of minimally invasive treatment options
have expanded the role of interventional radiology in the
management of hemorrhage for a variety of indications,
such as peptic ulcer bleeding, malignant diseases,
hemorrhagic Dieulafoy lesions and iatrogenic or trauma
bleeding [1, 6]. The technical aspects of TAE in the
current study were performed following the recommen-
dations described in the publication of Scandinavian
authors, providing diagnostic angiography within 24 h of
endoscopic hemostasis. The branches of the celiac trunk
and the superior mesenteric artery, and the artery
related to the peptic ulcer were identified according to
the hemoclip placed during the endoscopic procedure.
Microcatheter technique and coils were used routinely,
and the blind technique in exclusive cases only [12].
Risk assessment
The assessment of the medical charts of the patients
with acute NVUGI bleeding who were admitted to
our institution revealed a group of patients who expe-
rienced rebleeding episodes after emergent endoscopic
haemostasis. The most frequent endoscopic finding in this
cohort was Forrest I-IIb type ulcers and the Rockall
score ≥ 5. A further prospective study confirmed this
observation complying with the reports from literature
including the observation that the patient’s age of over
60 years may be a risk factor. The other criteria, except for
blood pressure and heart rate, like haemoglobin levels are
reported as insufficiently sensitive in determining the
severity of the upper gastrointestinal bleeding [13, 14];
however, patients from both groups who experienced
rebleeding in our study had a median haemoglobin level
of 8.2–8.7 g/dl before repeated haemostasis. The majority
of reports emphasize that patients undergoing a transar-
terial procedure for the evaluation and management of
haemorrhage are often poor surgical candidates due to the
hemodynamic instability, comorbid conditions and coagu-
lopathy [1, 7, 8]. In the current study, the patient condi-
tion in both groups was quite similar before repeated
haemostasis, including the incidence of comorbid condi-
tions, level of blood loss, shock index and coagulation
status complying with the recommendations [1, 7, 8]. The
total need for transfusion was not different among the






Rockall score 3 3/12% 7/14% 1.000
Rockall score 4–5 4/16% 11/22% 0.761
Rockall score 6–7 13/52% 21/42% 0.412
Rockall score 8–9 4/16% 10/20% 0.763
Rockall score 10–11 1/4% 1/2% 1.000
Shock index 0,1 > 0/0 3/6% 0.546
Shock index 0,5 > 6/24% 12/24% 1.000
Shock index 0,7 > 9/36% 15/30% 0.600
Shock index 1 > 10/40% 20/40% 1.000






Anticoagulants 2/8% 5/10% 1.000
Antiaggregants 6/24% 13/26.5% 0.814
NSAID (excluding Aspirine) 3/12% 12/24% 0.359
Table 4 Main outcomes
Outcomes PE+ PE− p
ICU needed 25 (100%) 40 (82%) 0,024
ICU stay, days, median (IQR) 3 (3-2) 3 (5-2) 0,352
Transfusion needed, no of patients 22 (88%) 40 (80%) 0,524
PRBC, units 4 (5-3) 4 (5-2) 0,399
FFP, units, (IQR) 2 (2-2) 3 (4-2) 0,013
Surgery, no of patients 2 (8%) 17 (35%) 0,012
Re-bleeding, no of patients 3 (12%) 11 22,4% 0,358
Hospital stay, days (IQR) 6 (10-6) 9 (11-6) 0,079
Mortality, no of patients 1 (4%) 8 16,3% 0,258
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groups, including the transfused amount of PRBC units,
while significantly more FFP units were needed for pa-
tients who did not undergo preventive TAE. The strategy
was preventive and the decision to perform prophylactic
preventive TAE was the decision of the duty personnel in
consensus with the consultant surgeon, consultant radi-
ologist and duty endoscopy specialist. This strategy
allowed to perform preventive TAE shortly after the inclu-
sion criteria were established and indirectly supported the
evidence that early TAE is associated with lower morbidity
and mortality [2, 15, 16]. It is difficult to pinpoint the au-
thor of the idea of preventive embolization, however, a
large part of clinical data and tactical recommendations
are published by Scandinavian authors [1, 2, 15, 16]. The
current study supports the reported positive experience
with preventive TAE. Both patient groups were at a high
risk of rebleeding after endoscopic hemostasis, and even if
the ICU and hospital stay was not different, the need for
surgical intervention was significantly higher in pa-
tients who did not undergo preventive TAE. Even
more, mortality was also higher, albeit not signifi-
cantly, probably due to a small sample size. The weak
points of our study were the relatively small sample
size and unpowered statistics. All the same, as in
other reports, the uncertain selection of criteria for
inclusion and the need for a larger cohort of patients
were the weaknesses of the study. The advantages in-
cluded the availability of the duty stuff for the defin-
ition of the inclusion criteria and the rather short
time span for performing preventive TAE.
Conclusion
Preventive TAE is a feasible, safe and effective minimally
invasive type of haemostasis, decreasing the risk of repeated
bleeding and preparing the patient for the definitive surgical
intervention when indicated. The availability of the duty
stuff and the performance of TAE soon after the indications
are defined increase the efficiency of the procedure.
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